Journal of Diagnostics Concepts & Practice ›› 2019, Vol. 18 ›› Issue (06): 623-629.doi: 10.16150/j.1671-2870.2019.06.004
• Academic trends at home and abroad • Previous Articles Next Articles
Received:2019-07-30
Online:2019-12-25
Published:2019-12-25
CLC Number:
| [1] |
Valent P, Orazi A, Steensma DP, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions[J]. Oncotarget, 2017, 8(43):73483-73500.
doi: 10.18632/oncotarget.19008 pmid: 29088721 |
| [2] |
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood,2016, 127(20):2391-2405.
doi: 10.1182/blood-2016-03-643544 URL |
| [3] |
Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes[J]. N Engl J Med, 2014, 371(26):2488-2498.
doi: 10.1056/NEJMoa1408617 URL |
| [4] |
Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis[J]. Nat Genet, 2012, 44(11):1179-1181.
doi: 10.1038/ng.2413 URL |
| [5] |
Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes[J]. Blood, 2015, 126(1):9-16.
doi: 10.1182/blood-2015-03-631747 pmid: 25931582 |
| [6] |
Malcovati L, Gallì A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia[J]. Blood, 2017, 129(25):3371-3378.
doi: 10.1182/blood-2017-01-763425 pmid: 28424163 |
| [7] |
Hansen JW, Westman MK, Sjö LD, et al. Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes[J]. Am J Hematol, 2016, 91(12):1234-1238.
doi: 10.1002/ajh.24554 URL |
| [8] |
Balleari E, Clavio M, Arboscello E, et al. Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes[J]. Leuk Res, 2011, 35(11):1472-1476.
doi: 10.1016/j.leukres.2011.05.025 URL |
| [9] | 张宏丽, 秦铁军, 徐泽锋, 等. 重组人EPO治疗较低危骨髓增生异常综合征的临床疗效分析[J]. 中华血液学杂志, 2014, 35(1):18-23. |
| [10] |
Garelius HK, Johnston WT, Smith AG, et al. Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome[J]. J Intern Med, 2017, 281(3):284-299.
doi: 10.1111/joim.12579 pmid: 27926979 |
| [11] |
List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion[J]. N Engl J Med, 2006, 355(14):1456-1465.
doi: 10.1056/NEJMoa061292 URL |
| [12] |
Santini V, Almeida A, Giagounidis A, et al. Randomized phase Ⅲ study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents[J]. J Clin Oncol, 2016, 34(25):2988-2996.
doi: 10.1200/JCO.2015.66.0118 URL |
| [13] | Cadenas-Cadenas FL, Lumbreras E, Xicoy B, et al.Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients with Del(5q)- Preliminary Blinded Analysis of the European Sintra-REV Trial[A].[60th American Society of Hematology Annual Meeting oral presentation]Blood 2018, 132(suppl 1):468. |
| [14] |
Xiao L, Qi Z, Qiusheng C, et al. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression[J]. Am J Hematol, 2012, 87(1):26-31.
doi: 10.1002/ajh.22184 pmid: 22038646 |
| [15] | Stahl M, Bewersdorf JP, Giri S, et al. Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis[J]. Haematologica,2019,pii:haematol. 2019.219345. |
| [16] | Zeidan AM, Zhu W, Stahl M, et al. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis[J]. Leuk Lymphoma, 2019:1-7. |
| [17] |
Baek DW, Lee YJ, Kim H, et al. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts[J]. Ann Hematol, 2018, 97(12):2309-2317.
doi: 10.1007/s00277-018-3458-7 URL |
| [18] |
Jabbour E, Short NJ, Montalban-Bravo G, et al. Rando-mized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN[J]. Blood, 2017, 130(13):1514-1522.
doi: 10.1182/blood-2017-06-788497 pmid: 28774880 |
| [19] | Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial[J]. Lancet Haematol, 2017, 4(3):e127-e136. |
| [20] |
Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia[J]. Cancer, 2014, 120(12):1838-1846.
doi: 10.1002/cncr.28663 URL |
| [21] | Kantarjian HM, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial[J]. Lancet Haematol, 2018, 5(3):e117-e126. |
| [22] |
Santini V. Anemia as the main manifestation of myelodysplastic syndromes[J]. Semin Hematol, 2015, 52(4):348-356.
doi: 10.1053/j.seminhematol.2015.06.002 URL |
| [23] |
Angelucci E, Li J, Greenberg PL, et al. Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS): outcomes from the randomized, double-blind telesto study[J]. Blood, 2018, 132:234.
doi: 10.1182/blood-2018-99-111134 URL |
| [24] | Fenaux P, Platzbecker U, Mufti G J, et al. The medalist trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell(RBC) transfusions[J]. Blood, 2018, 132:1. |
| [25] |
Steensma DP, Platzbecker U, van Eygen K, et al. Imetelstat treatment leads to durable transfusion independence (TI) in RBC Transfusion Dependent (TD), Non-Del(5q) lower risk MDS relapsed/refractory to erythropoiesis-stimu-lating agent (ESA) who are lenalidomide (LEN) and HMA naïve[J]. Blood, 2018, 132:463.
doi: 10.1182/blood-2018-99-114877 URL |
| [26] |
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase Ⅲ study[J]. Lancet Oncol. 2009 Mar; 10(3):223-232.
doi: 10.1016/S1470-2045(09)70003-8 URL |
| [27] |
Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J]. Blood, 2007, 109(1):52-57.
doi: 10.1182/blood-2006-05-021162 pmid: 16882708 |
| [28] |
Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial[J]. J Clin Oncol, 2009, 27(23):3842-3848.
doi: 10.1200/JCO.2008.19.6550 pmid: 19528372 |
| [29] |
Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the 'real-world': an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada[J]. Br J Haematol, 2018, 181(6):803-815.
doi: 10.1111/bjh.15273 URL |
| [30] |
Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes[J]. N Engl J Med, 2016, 375(21):2023-2036.
doi: 10.1056/NEJMoa1605949 URL |
| [31] |
Chang CK, Zhao YS, Xu F, et al. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes[J]. Br J Haematol, 2017, 176(4):600-608.
doi: 10.1111/bjh.14455 URL |
| [32] | Xie M, Jiang Q, Li L, et al. HAG (homoharringtonine, cytarabine, G-CSF) regimen for the treatment of acute myeloid Leukemia and myelodysplastic syndrome: A meta-analysis with 2,314 participants[J]. PLoS One, 2016, 11(10):e0164238. |
| [33] |
Wu L, Li X, Chang C, et al. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study[J]. Leuk Lymphoma, 2016, 57(6):1367-1374.
doi: 10.3109/10428194.2015.1096351 URL |
| [34] | 中华医学会血液学分会.骨髓增生异常综合征中国诊断与治疗指南(2019年版)[J]. 中华血液学杂志, 2019, 40(2):89-97. |
| [35] | Garcia-Manero G, Roboz G, Walsh K, et al. Guadecitabine Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial[J]. Lancet Haematol, 2019, 6(6):e317-e327. |
| [36] |
Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethyla-ting drugs (ONTIME): a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2016, 17(4):496-508.
doi: S1470-2045(16)00009-7 pmid: 26968357 |
| [37] |
Navada S, Garcia-Manero G, Atallah EL, et al. Phase 2 expansion study of oral rigosertib combined with azacitidine (AZA) in patients (Pts) with higher-risk (HR) myelodysplastic syndromes (MDS): Efficacy and safety results in HMA treatment naǐve & relapsed (Rel)/Refractory (Ref) Patients[J]. Blood, 2018, 132(suppl 1):230.
doi: 10.1182/blood-2018-99-119259 URL |
| [38] |
Taylor J, Coleman M, Alvarez J, et al. Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents[J]. Blood, 2018, 132(suppl 1):233.
doi: 10.1182/blood-2018-99-113840 URL |
| [39] | Garcia-Manero G, Sasaki K, Montalban-Bravo G, et al. A phase Ⅱ study of nivolumab or ipilimumab with or without azacitidine for patients with myelodysplastic syndrome (MDS)[J]. Blood, 2018, 132(suppl 1):465. |
| [40] |
Gerds AT, Scott B, Greenberg PL, et al. PD-L1 blockade with atezolizumab in higher-risk myelodysplastic syndrome: An initial safety and efficacy analysis[J]. Blood, 2018, 132(suppl 1):466.
doi: 10.1182/blood-2018-99-118577 URL |
| [41] |
Brierley CK, Steensma DP. Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?[J]. Curr Opin Hematol, 2016, 23(2):167-174.
doi: 10.1097/MOH.0000000000000217 URL |
| [42] |
Yahng SA, Kim M, Kim TM, et al. Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts[J]. Oncotarget, 2017, 8(7):12342-12354.
doi: 10.18632/oncotarget.12511 URL |
| [1] | . [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(04): 434-437. |
| [2] | CHANG Rui, YANG Yanzhao, KONG Deyan, XU Jiaxu, CAO Qiqi, YANG Wenjie, YAN Fuhua, DONG Haipeng. Application of different tube voltage-current protocol in combination with KARL iterative reconstruction in CT chest scanning for novel coronavirus pneumonia screening [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 182-187. |
| [3] | YE Chenglin, YAO Yonghua, CHEN Zhen, JIA Lin. Application of plastic-embedded bone marrow biopsy in diagnosing myelodysplastic syndrome with thrombocytopenia [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 177-181. |
| [4] | XIAO Chao, TAO Ying, SONG Luxi, ZHAO Youshan, WU Lingyun, CHANG Chunkang. Clinical analysis of 88 patients with myeloproliferative neoplasm [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 115-121. |
| [5] | . [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 111-114. |
| [6] | . [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(02): 104-110. |
| [7] | LU Hongyu, CAO Yafeng, GU Jun, WANG Jing, CHEN Mei, SONG Luxi. Diagnostic value of nerve electrophysiological studies for Bortezomib-induced peripheral neuropathy in multiple myeloma patients [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(06): 640-644. |
| [8] | SONG Dandan, CHANG Chunkang, GUO Juan, XU Feng, ZHAO Youshan, WU Lingyun. The abnormal percentage of bone marrow macrophages and its clinical significances in myelodysplastic syndromes [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(04): 439-443. |
| [9] | . [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(01): 123-126. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
